Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give
 to participants and to look at how well BAY 2433334 works on top of antiplatelet therapy in
 patients following a recent non cardioembolic ischemic stroke which occurs when a blood clot
 that has not formed in the heart travelled to the brain. BAY 2433334, works by blocking a
 step of the blood clotting process in our body and thins the blood and is a so called oral
 FXIa inhibitor.
Inclusion Criteria:

 -  Participant must be 45 years of age and older at the time of signing the informed
 consent

 -  Non-cardioembolic ischemic stroke with

 -  persistent signs and symptoms of stroke lasting for ≥ 24 hours OR

 -  acute brain infarction documented by computed tomography (CT) or MRI AND

 -  with the intention to be treated with antiplatelet therapy during the study
 conduct

 -  Imaging of brain (CT or MRI) ruling out hemorrhagic stroke or another pathology that
 could explain symptoms (e.g. brain tumor, abscess, vascular malformation)

 -  Severity of index event nearest the time of randomization:

 -  Part A: minor stroke (defined as National Institutes of Health Stroke Scale
 (NIHSS) ≤ 7) can be enrolled

 -  Part B: participants with minor or moderate stroke and NIHSS ≤ 15 can be
 enrolled. Participants undergoing thrombolysis or endovascular therapy
 (mechanical thrombectomy) can be enrolled but at the earliest 24 hours after the
 intervention

 -  Randomization within 48 hours after the onset of symptoms of the index event (or after
 patients were last known to be without symptoms in case of wake-up stroke)

 -  Ability to conduct an MRI either before randomization or within 72 hours after
 randomization

 Exclusion Criteria:

 -  Prior ischemic stroke within last 30 days of index event

 -  History of atrial fibrillation or suspicion of cardioembolic source of stroke

 -  Dysphagia with inability to safely swallow study medication

 -  Contraindication to perform brain MRI

 -  Part A only: thrombolysis or endovascular therapy (mechanical thrombectomy) performed
 for index event

 -  Active bleeding; known bleeding disorder, history of major bleeding (intracranial,
 retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding
 within last 6 months of randomization.